Market news

Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The capital raise comes after a sharp pullback in Dianthus Therapeutics' share price. The stock fell 4.99% over the last session, 8.83% across the past week and 15.11% over 30 days. However, the 90-day share price return of 2.04% and a year-to-date share price gain of 135.48% suggest that momentum has...

Dianthus Therapeutics has delivered a very large 3 year return, which puts a lot of focus on whether the current share price still lines up with what its balance sheet actually supports. With the stock last closing at US$93.44, the open question is how that level stacks up against the book value backing each share. Over the past 3 years the stock has gained roughly 7x. Anyone looking at Dianthus Therapeutics now has to ask whether that kind of move is still grounded in the company’s...

Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $139.36, accordin

On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates that touched nearly every program the company runs. For a clinical-stage biotech with no approved product yet, the update reads less like a routine earnings drop and more like a status report on three separate autoimmune disease bets happening […]

Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $139.36, accordin

NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on September 1, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to ac

Anne McGeorge, Director, on August 10, 2026, sold 7,750 shares in Dianthus Therapeutics (DNTH) for $

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across...

NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on August 3, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to accepta